大動脈弁の世界市場：現状分析と予測（2021年～2027年）

世界の大動脈弁の市場規模は、予測期間（2021年～2027年）中に約13％のCAGRで成長すると予測されています。

心臓弁膜症の有病率の上昇と高齢者人口の増加は、大動脈弁市場の成長を促す一つの要因となっています。さらに、世界的に弁膜症が増加していることも、市場の成長を促進しています。

当レポートでは、世界の大動脈弁市場について調査しており、市場の洞察、市場の動向、競合シナリオ、企業概要など、包括的な情報を提供しています。

目次

第1章 市場のイントロダクション

• 市場の定義
• 制限
• ステークホルダー
• レポートで使用される通貨

第2章 調査方法または仮定

• 大動脈弁市場の調査プロセス
• 大動脈弁市場の調査手法
• 予測方法
• 回答者のプロファイル
• 大動脈弁市場調査の主な目的

第3章 市場の要約

第4章 エグゼクティブサマリー

第5章 大動脈弁市場におけるCOVID-19の影響

第6章 大動脈弁市場の収益（2019年～2027年）

第7章 市場の洞察：弁タイプ別

• 組織/生物的
• 機械的

第8章 市場の洞察：縫合糸タイプ別

• 縫合
• 無縫合

第9章 市場の洞察：施術別

• 開腹手術
• 低侵襲手術

第10章 市場の洞察：エンドユーザー別

• 病院
• 外来手術センター

第11章 市場の洞察：地域別

• 北米
  • 米国
  • カナダ
  • その他の北米
• 欧州
  • ドイツ
  • 英国
  • フランス
  • イタリア
  • スペイン
  • その他の欧州
• アジア太平洋
  • 中国
  • 日本
  • インド
  • オーストラリア
  • その他のアジア太平洋
• その他

第12章 大動脈弁市場力学

• 市場促進要因
• 市場の課題
• 影響分析

第13章 大動脈弁市場の機会

第14章 大動脈弁市場の動向

第15章 法規制の枠組み

第16章 需要と供給側分析

• 需要側分析
• 供給側分析
  • 主要製品の発売
  • 主要企業のパートナーシップ
  • 主要企業の拡大
  • 主要な合併と買収

第17章 バリューチェーン分析

第18章 競合シナリオ

• ポーターのファイブフォース分析
  • サプライヤーの交渉力
  • バイヤーの交渉力
  • 業界の競争
  • 代替品の入手可能性
  • 新規参入業者の脅威

第19章 会社概要

• Boston Scientific Corporation
• Edwards Lifesciences Corporation
• CryoLife Inc.
• Medtronic plc
• LivaNova PLC
• Abbott Laboratories
• JenaValve Technology Inc.
• Thubrikar Aortic Valve Inc.
• LifeNet Health Inc.
• Coroneo Inc.

第20章 免責事項

Global Aortic valve Market is anticipated to grow with an elevated CAGR of around 13% over the forecast period (2021-2027). The aortic valve allows blood to flow in the right direction in the heart. It separates the main pump chamber of the heart (left ventricle) from the main arteries that supply the body with oxygen-rich blood (aorta). Each time the ventricle contracts, the aortic valve opens, allowing blood to flow from the left ventricle to the aorta. When the ventricles relax, the aortic valve closes and prevents blood from flowing back into the ventricles.

The growing prevalence of heart valve disease coupled with the rising geriatric population is another factor contributing to the growth of the aortic valve market. For instance, according to the United Nations, In 2019, 13.2% of the worldwide population was aged 60 years or above. Further, it is anticipated that nearly 21.4% of the total worldwide population will be aged 60 years or over by 2050. In view of these facts, there is a rising prevalence of aortic regurgitation which creates the need for heart valve replacement which in turn is driving the aortic valve market globally.

Furthermore, The rising worldwide demand for the aortic valve is because of the increase in valvular diseases globally. For instance, as per CDC, About 2.5% of the U.S. population has valvular heart disease, but it is more common in older adults. About 13% of people born before 1943 have valvular heart disease. However, some of the restraints in the market include stringent regulatory framework and product failure and recalls are impeding the growth of this market all over the world. Boston Scientific Corporation, Edwards Lifesciences Corporation, CryoLife Inc., Medtronic plc, LivaNova PLC, Abbott Laboratories, JenaValve Technology Inc., Thubrikar Aortic Valve Inc., LifeNet Health Inc., Coroneo Inc, are some of the prominent players operating in the aortic valve market. Several M&As along with partnerships have been undertaken by these players to facilitate customers with aortic valves.

Insights Presented in the Report

"Amongst Valve Type, Tissue/Biological segment holds the major share"

Based on valve type, the market is bifurcated into tissue/biological type and mechanical type. The tissue/biological type segment occupied the major share of the artificial blood vessels market in 2020 and it is expected to grow with a substan]ial CAGR in the upcoming years owing to the various advantages associated with this type of valve such as avoiding lifelong warfarin therapy to prevent the formation of blood clots, long-term durability, and free from reoperation for valve degeneration. Owing to this, many key industry players are launching new and advanced products in the market. For example, in September 2021, Abbott announced that the FDA has approved the company's Epic Plus and Epic Plus Supra Stented Tissue Valves to improve therapy options for people with aortic or mitral valve disease.

"Amongst Suture Type, Sutureless segment holds the major share"

Based on suture type, the aortic valve market is bifurcated into sutured and sutureless. The sutureless segment occupied the major share of the aortic valve market in 2020 and it is expected to grow with a substantial CAGR in the upcoming years owing to its reduced duration of cross-clamp and cardiopulmonary bypass (CPB) procedures compared to sutured valves.

"Amongst Procedure, Minimally Invasive Surgery segment holds the major share"

Based on the procedure, the market is bifurcated into open surgery and minimally invasive surgery. The minimally invasive surgery segment occupied the major share of the aortic valve market in 2020 and it is expected to grow with a substantial CAGR in the upcoming years as minimally invasive surgery causes less trauma to the patients and facilitates faster recovery than open-heart surgery as the geriatric population takes more time to get recover from surgery.

"Amongst End-Users, hospitals segment holds the major share"

Based on end-users, the market is fragmented into hospitals, and ambulatory surgical centers. In 2020, hospitals segment grabbed a considerable market share, and it is expected to grow at a significant CAGR during the forecast period owing to the increasing construction of hospitals and a surge in the number of heart surgeries in the hospital setting. However, ambulatory surgical centers are also likely to witness the fastest growth during the forecast period.

"Europe represents one of the largest markets of aortic valve market"

For a better understanding of the market dynamics of the aortic valve market, a detailed analysis was conducted for different regions across the globe including North America (the U.S, Canada, and the Rest of North America), Europe (Germany, France, Spain, United Kingdom, Italy, and Rest of Europe), Asia-Pacific (China, India, Australia, Japan, and Rest of APAC), Rest of World has been conducted. Europe constitutes a major market for the aortic valve market industry and generated revenue of USD XX Million in 2020 owing to strong healthcare infrastructure and growing adoption of the aortic valve in the region.

Reasons to buy this report:

• The study includes market sizing and forecasting analysis validated by authenticated key industry experts

• The report presents a quick review of overall industry performance at one glance

• The report covers an in-depth analysis of prominent industry peers with a primary focus on key business financials, product portfolio, expansion strategies, and recent developments

• Detailed examination of drivers, restraints, key trends, and opportunities prevailing in the industry

• The study comprehensively covers the market across different segments

• Deep dive regional level analysis of the industry

Customization Options:

The global aortic valve market can further be customized as per the requirement or any other market segment. Besides this, UMI understands that you may have your own business needs, hence feel free to connect with us to get a report that completely suits your requirements.

TABLE OF CONTENTS

1 MARKET INTRODUCTION

• 1.1. Market Definitions
• 1.2. Limitation
• 1.3. Stakeholders
• 1.4. Currency used in Report

2 RESEARCH METHODOLOGY OR ASSUMPTION

• 2.1. Research Process of the Aortic Valve Market
• 2.2. Research Methodology of the Aortic Valve Market
• 2.3. Forecasting Method
• 2.4. Respondent Profile
• 2.5. Main Objective of the Aortic Valve Market Study

3 MARKET SYNOPSIS

4 EXECUTIVE SUMMARY

5 AORTIC VALVE MARKET COVID-19 IMPACT

6 AORTIC VALVE MARKET REVENUE, 2019-2027F

7 MARKET INSIGHTS BY VALVE TYPE

• 7.1. Tissue/ Biological
• 7.2. Mechanical

8 MARKET INSIGHTS BY SUTURE TYPE

• 8.1. Sutured
• 8.2. Sutureless

9 MARKET INSIGHTS BY PROCEDURE

• 9.1. Open Surgery
• 9.2. Minimally Invasive Surgery

10 MARKET INSIGHTS BY END-USERS

• 10.1 Hospitals
• 10.2 Ambulatory Surgery Centers

11 MARKET INSIGHTS BY REGION

• 11.1. North America
  • 11.1.1 US
  • 11.1.2 Canada
  • 11.1.3 Rest of North America
• 11.2 Europe
  • 11.2.1 Germany
  • 11.2.2 UK
  • 11.2.3 France
  • 11.2.4 Italy
  • 11.2.5 Spain
  • 11.2.6 Rest of Europe
• 11.3 Asia-Pacific
  • 11.3.1 China
  • 11.3.2 Japan
  • 11.3.3 India
  • 11.3.4 Australia
  • 11.3.5 Rest of Asia-Pacific
• 11.4 Rest of World

12 AORTIC VALVE MARKET DYNAMICS

• 12.1 Market Drivers
• 12.2 Market Challenges
• 12.3 Impact Analysis

13 AORTIC VALVE MARKET OPPORTUNITIES

14 AORTIC VALVE MARKET TRENDS

15 LEGAL & REGULATORY FRAMEWORK

16 DEMAND AND SUPPLY SIDE ANALYSIS

• 16.1 Demand Side Analysis
• 16.2 Supply Side Analysis
  • 16.2.1 Top Product Launches
  • 16.2.2 Top Business Partnerships
  • 16.2.3 Top Business Expansions
  • 16.2.4 Top Merger and Acquisitions

17 VALUE CHAIN ANALYSIS

18 COMPETITIVE SCENARIO

• 18.1 Porter's Five forces analysis
  • 18.1.1 Bargaining power of Supplier
  • 18.1.2 Bargaining power of Buyer
  • 18.1.3 Industry Rivalry
  • 18.1.4 Availability of Substitute
  • 18.1.5 Threat of new Entrants

19 COMPANY PROFILED

• 19.1 Boston Scientific Corporation
• 19.2 Edwards Lifesciences Corporation
• 19.3 CryoLife Inc.
• 19.4 Medtronic plc
• 19.5 LivaNova PLC
• 19.6 Abbott Laboratories
• 19.7 JenaValve Technology Inc.
• 19.8 Thubrikar Aortic Valve Inc.
• 19.9 LifeNet Health Inc.
• 19.1 Coroneo Inc.

20 DISCLAIMER